Skip to main content
SpringerLink
Log in

Development of Hormone Refractory Tumors: Adaption Versus Clonal Selection

  • Conference paper
Hormone-Related Malignant Tumors

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 118))

Abstract

One of the most common characteristics of cancers is their ability to develop resistance to chemotherapy and/or hormonal manipulation to which they were initially responsive (Skipper et al. 1978; Goldie and Coldman 1979, Isaacs 1982b; Ling 1982). For example, there is an initial response rate of prostatic cancer patients to androgen ablation of about 70%–80%. However, essentially all of these patients eventually relapse to an androgen-independent state in which further antiandrogen therapy is no longer effective. Following relapse, all further attempts to ablate the low level of non-testicular androgens remaining following castration, estrogen or luteinzing hormone releasing hormone (LH-RH) analogue therapy by means of hypophysectomy, adrenalectomy, or administration of direct-acting antiandrogens have proven unsuccessful in stopping the continuous tumor growth in this androgen-independent state (Scott et al. 1980; Schulze et al. 1987).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Byar DP, Mostofi FK (1972) Carcinoma of the prostate: prognostic evaluation of certain pathological features in 208 radical prostatectomies, examined by the step section technique. Cancer 30: 5–13

    Article  PubMed  CAS  Google Scholar 

  • Crawford ED, MeLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, Blumenstein B (1988) Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. J Urol 139: 339A

    Google Scholar 

  • Devesa SS, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935–1974. J. Natl Cancer Inst. 60: 545–571

    PubMed  CAS  Google Scholar 

  • Dunning WF (1963) Prostate cancer in the rat. NCI Monogr 12: 351–369

    CAS  Google Scholar 

  • Durham, SK, Dietze, AE (1986) Prostatic adenocarcinoma with and without metastasis to bone in dogs. J Am Vet Assoc 12: 1432–1436

    Google Scholar 

  • Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy. 5 year follow-up. Eur Urol 6: 145–148

    PubMed  CAS  Google Scholar 

  • Goldie GH, Coldman AJ (1979) A mathematical model formulating the drug sensitivity of tumors to their spontaneous metastatic rate. Cancer Treat Rep 63: 1727

    PubMed  CAS  Google Scholar 

  • Hakansson L, Troupe C (1974) On the presence within tumors of clones that differ in sensitivity to cytostatic drugs. Acta Pathol. Microbiol. Scand (A) 82: 32

    Google Scholar 

  • Hayashi T, Taki Y, Ikai K, Hiura M, Kiriyama T, Shizuki K (1987) Latent and clinically manifest prostatic carcinoma. Prostate 10: 275–279

    Article  PubMed  CAS  Google Scholar 

  • Isaacs JT (1982a) Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327—AT and -G rat adenocarcinomas. Cancer Res 42: 5010–5014

    PubMed  CAS  Google Scholar 

  • Isaacs JT (1982b) Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC, Boca Raton, pp 139–156

    Google Scholar 

  • Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–18

    Article  PubMed  CAS  Google Scholar 

  • Isaacs JT (1987) Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: Rodgers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F, Forton R (eds) benign prostatic hyperplasia, vol 2. NIH publication 87–2881. NIH, Bethesda, pp 85–94

    Google Scholar 

  • Isaacs JT, Coffey DS (1984) Adaptation vs. selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 —H adenocarcinoma. Cancer Res 41: 5070–5075

    Google Scholar 

  • Isaacs JT, Heston, WDW, Weissman, RM Coffey, DS (1978) Animal models of the hormon-sensitive and -insensitive prostatic adenocarcinomas: Dunning R-3327-H, R3327-HI, and $-3327-AT. Cancer Res 38: 4353–4359

    PubMed  CAS  Google Scholar 

  • Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Duning R 3327 rat prostatic adenocarcinoma system. Cancer Res 42: 2353–2361

    PubMed  CAS  Google Scholar 

  • Isaacs, JT, Isaacs WB, Feitz WFJ Scheres J. (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in delveloping methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261–281.

    Article  PubMed  CAS  Google Scholar 

  • Jesik CJ, Holland JM, Lee C (1982) An anatomic and histologic study of the rat prostate. Prostate 3: 81–97

    Article  PubMed  CAS  Google Scholar 

  • Kastendieck H (1980) Correlation between atypical primary hyperplasia and carcinoma of the prostate. Histologic studies on 180 total prostatectomies due to manifest carcinoma. Path Res Pract 169: 366–387

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: Devita VT Hellman S, Rosenberg S (eds) Important advances in oncology. Lippincott, Philadelphia, pp 193–217

    Google Scholar 

  • Labrie F, Dupont A, Belanger A, Emond J, Monfette G (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J Drug Dev 1 (suppl 1)34–51

    Google Scholar 

  • Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer- J Urol 128: 335–340

    PubMed  CAS  Google Scholar 

  • Lesser B, Bruchovsky N (1973) The effects of testosterone, 5a-dihydrotestosterone, and adenosine 3’, 5’-monophosphate on cell proliferation and differentiation in rat prostate. Biochim. Biophys. Acta 308: 426–437

    PubMed  CAS  Google Scholar 

  • Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311: 1281–1286

    Article  Google Scholar 

  • Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC, Boca Raton, pp 1–19

    Google Scholar 

  • McNeal JE (1983) Monographs in urology. In: Stamey TA (ed) Custom Princeton, vol 4, pp 3–33

    Google Scholar 

  • Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG, Littleton,MA, pp 175–200

    Google Scholar 

  • Mostofi FK, Sesterhenn J (1981) The role of prostatic acid phosphatase in histological diagnosis of carcinoma of the prostate. Proceedings of the seventy-sixth annual meeting of the American Urological Association, Boston, Abstract 42

    Google Scholar 

  • Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens of stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 136: 1030–1034

    PubMed  CAS  Google Scholar 

  • Pollard M (1980) The Pollard tumors. In: Murphy GP (ed) Models for Prostate cancer. Liss, New York, pp 293–302

    Google Scholar 

  • Prout GR, Leiman B, Daly JJ, MacLoughlin RA, Griffin PP, Young HH (1976) Endocrine changes after diethylstilbestrol therapy. Urology 7: 148–155

    Article  PubMed  CAS  Google Scholar 

  • Rivenson A, Silverman J (1979) The prostatic carcinoma in laboratory animals. Invest Urol 16: 468–478

    PubMed  CAS  Google Scholar 

  • Sandford NL, Searle JW, Kerr JFR (1984) Successive waves of apoptosis in the rat prostate after regulated withdrawal of testosterone stimulation. Pathlogy 16: 406–410

    CAS  Google Scholar 

  • Schroeder FH, Klijn JG, de Jong FH (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137: 912–918

    PubMed  CAS  Google Scholar 

  • Schulze H, Isaacs, JT, Coffey DS (1987) A critical review of the concept of total androgen ablation in the treatment of prostate cancer. In: Murphy GP et al. (eds) Prostate cancer. Part A. Prog Clin Biol Res 243: 1–19

    Google Scholar 

  • Schulze H, Kaldenhoff H, Senge T, Westfälische Prostata-Karzinom study group (1988) Evaluation of total versus partial androgen blockade in the treatment of advanced protatic cancer. Urol Int 43: 193–1

    Article  PubMed  CAS  Google Scholar 

  • Scott, WW, Menon M Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936

    PubMed  CAS  Google Scholar 

  • Shain SA, McCullough B, Segaloff A (1975) Spontaneous adenocarcinoma of the ventral prostate of the aged AXC rats. J Natl Cancer Inst 55: 177–180

    PubMed  CAS  Google Scholar 

  • Shain SA, McCullough B, Nitchuk M, Boesel RW (1977) Prostatic carcinogenesis in the AXC rat. Oncology 34: 114

    Article  PubMed  CAS  Google Scholar 

  • Sinha AA, Blackard, CE, Seal USA (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 40: 2836–2850

    Article  PubMed  CAS  Google Scholar 

  • Skipper HE, Schabel FM, Lloyd MM (1978) Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Exp Ther Kinetics 15: 207–217

    CAS  Google Scholar 

  • Smolev JK, Heston WD, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327—H prostatic adenocarcinoma. An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273–287

    PubMed  CAS  Google Scholar 

  • Thompson JB, Greenberg E, Pazianos A, Pearson OH (1974) Hypophysectomy in metastatic prostate cancer. NY State J Med 74: 1006–1008

    CAS  Google Scholar 

  • Viola MV, Fromowitz F, Oravez MS, Deb S., Finket G, Lundy J, Harel P, Thor A, Schlom J (1986) Expression of ras oncogene p21 in prostatic cancer. Engl. J Med 314: 133–137

    Article  CAS  Google Scholar 

  • Voigt W, Dunning WF (1974) In vivo metabolism of testosterone-3H in R-3327, an androgen—sensitive rat prostatic adenocarcinoma. Cancer Res 34: 1447–1450

    PubMed  CAS  Google Scholar 

  • Voigt W, Feldman, M, Dunning WF (1975) 5a-Dihydrotestosterone binding proteins and androgen sensitivity in prostatic cancers of copenhagen rats. Cancer Res 35: 1840–1846

    Google Scholar 

  • Wake N, Isaacs JT, Sandberg AA (1982) Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42: 4131–4142

    PubMed  CAS  Google Scholar 

  • Ward JM, Reznik G, Stinson SF, Lattatuda CP, Longfellow DG, Cameron TP (1980) Histogenesis and morphology of naturally occuring prostatic carcinoma in the ACI/segHapBR rat. Lab Invest 43: 517–522

    PubMed  CAS  Google Scholar 

  • Ware JL (1987) Prostate tumor progression and metastasis. Biochim. Biophys. Acta 907: 279–298

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Abteilung, Marienhospital, Universität Bochum, 4690, Herne, Germany

    H. Schulze

  2. Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    J. T. Isaacs

Authors
  1. H. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. T. Isaacs
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Frauenklinik, Medizinische Einrichtungen, Universität Düsseldorf, Moorenstraße 5, 4000, Düsseldorf, Germany

    Lutwin Beck

  2. Gerhard Domagk-Institut für Pathologie, Westfälische Wilhelms-Universität Münster, Domagkstraße 17, 4400, Münster, Germany

    Ekkehard Grundmann

  3. Urologische Klinik, Universität Düsseldorf, Moorenstraße 5, 4000, Düsseldorf, Germany

    Rolf Ackermann

  4. Chirurgische Klinik und Poliklinik I, Universität Düsseldorf, Moorenstraße 5, 4000, Düsseldorf, Germany

    Hans-Dietrich Röher

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin·Heidelberg

About this paper

Cite this paper

Schulze, H., Isaacs, J.T. (1990). Development of Hormone Refractory Tumors: Adaption Versus Clonal Selection. In: Beck, L., Grundmann, E., Ackermann, R., Röher, HD. (eds) Hormone-Related Malignant Tumors. Recent Results in Cancer Research, vol 118. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83816-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83816-3_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-83818-7

  • Online ISBN: 978-3-642-83816-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation